To report a case of atrial fibrillation in a male patient with metastatic breast cancer during treatment with utidelone.
Key Findings:
The patient developed atrial fibrillation approximately 24 hours after the last infusion of utidelone, highlighting a potential link.
Initial cardiological evaluations were normal prior to treatment, indicating no pre-existing conditions.
A close temporal association between utidelone administration and the onset of arrhythmia suggests a potential link.
Interpretation:
While a definitive causal relationship cannot be established, the case underscores the need for vigilant cardiac monitoring during utidelone treatment to mitigate risks.
Limitations:
The case is based on a single patient, limiting generalizability.
No prior reports of atrial fibrillation associated with utidelone exist in the literature.
Lack of long-term follow-up data on the patient.
Conclusion:
This case highlights the potential for utidelone to induce arrhythmias, emphasizing the importance of cardiac monitoring specifically during utidelone treatment.
